Immunovia announces positive update on physician experience program with IMMray™ PanCan-d
LUND, SWEDEN – Immunovia AB (Nasdaq Stockholm: IMMNOV) today announced positive feedback from its physician experience program for the IMMray™ PanCan-d test in the U.S., which is nearing completion. The program has included 23 high risk surveillance centers around the U.S. thus far, and physicians have showed substantial interest in the use of IMMray™ PanCan-d to detect early-stage pancreatic cancer. Immunovia’s physician experience program was designed for providers in the U.S. to gain clinical experience using the IMMray™ PanCan-d test. Feedback from participating physicians